Item 5. Market for Registrant’s Common Equity
ITEM 5 MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER
MATTERS, AND ISSUER PURCHASE OF EQUITY SECURITIES
COMMON STOCK
Our common stock is traded on the NYSE American exchange under the symbol LODE. The last reported sale price of our common stock on the NYSE American on February 26, 2024, was $0.46 per share. At February 26, 2024, the number of holders of record was 490.
SALE OF UNREGISTERED SECURITIES
On June 21, 2023, September 1, 2023, December 4, 2023 and December 5, 2023, the Company issued an aggregate of 475,930 shares of unregistered restricted common shares with a fair value of $211,562 to Alvin Fund in lieu of cash payments for interest under the Alvin Fund 2022 Note.
On August 25, 2023, the Company issued 963,074 shares of unregistered common stock with a fair value of $482,500 to Northern Comstock as payment for obligations due under the Northern Comstock operating agreement.
On February 14, 2023, the Company issued 410,959 shares of unregistered restricted common stock with a fair value of $150,000 to Leviston Resources LLC (“Leviston”) as payment for due diligence fees under the 2023 Leviston Sales Agreement (as defined below).
On October 25, 2022, the Company issued 605,620 shares of common stock to Alvin Fund for an aggregate sales price of $250,000 at an average price per share of $0.41 in connection with the placement of a $2,000,000 short-term promissory note.
On October 5, 2022, the Company sold 1,000,000 shares of unregistered securities to a single investor at a price of $0.375 per common share for net proceeds of $375,000.
On August 26, 2022, the Company issued 802,295 shares of unregistered restricted common stock with a fair value of $482,500 to Northern Comstock as payment for obligations due under the Northern Comstock operating agreement.
On June 21, 2022, the Company entered into an equity purchase agreement with Tysadco for the private placement of 3,076,923 common shares at a purchase price of $0.65 per share. The Company paid $140,000 in cash and delivered 57,143 common shares with a fair value of $40,000 to the placement agent in connection with such sale. The Company issued 428,571 unregistered common shares with a fair value of $300,000 in commitment fees.
On May 20, 2022, the Company cancelled 720,000 common shares returned by a previous employee and former owner of MANA.
On April 12, 2022, the Company issued 136,986 unregistered common shares with a fair value of $200,000 in due diligence fees as part of the 2022 Leviston Sales Agreement (as defined below).
On April 7, 2022, the Company issued 1,500,000 unregistered common shares with a fair value of $2,050,000 as part of the acquisition of the Haywood Property from Decommissioning Services.
On February 28, 2022, the Company and the other parties to the LP Biosciences LLC (“LP Biosciences”) transactions mutually agreed to terminate the transaction entered into in 2021. In connection with the termination, 3,500,000 restricted shares of the Company’s common stock were transferred back to the Company for cancellation upon receipt.
EQUITY COMPENSATION PLAN INFORMATION
See Item 11, Executive Compensation , for information on plans approved by our stockholders.
DIVIDEND POLICY
We have never declared or paid any dividends on our common stock. We do not anticipate paying any dividends on our common stock in the foreseeable future. We currently intend to retain future earnings, if any, to finance operations and expand
57
our business. Any future decision to pay cash dividends will be at the discretion of the Board of Directors and will depend upon our financial condition, operating results, capital requirements and other relevant factors.
ITEM 6 [RESERVED]
58